On Wednesday, Following Stocks were among the “Top Priority Stocks” For Traders – Zogenix, (NASDAQ:ZGNX), BioMarin Pharmaceutical (NASDAQ:BMRN), Skyworks Solutions (NASDAQ:SWKS), Opko Health (NYSE:OPK)
Zogenix, Inc. (NASDAQ:ZGNX) shares picked down -6.47%, and closed at $1.30. The stock volatility for the week is 3.99%, while for the month remained 7.25%. The company holds consensus target price of $2.75.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed 0.07 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 108.10% and Annual EPS growth for the past 5 years is considered as 14.90%.
The mean recommendation of analysts for this stock is 1.40. (Where 1=Buy, 5=Sale).
Zogenix, Inc. (ZGNX) a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its marketed product includes Zohydro ER, an extended-release formulation of hydrocodone for the treatment of severe chronic pain. The company also develops ZX008, a low-dose fenfluramine for the treatment of Dravet syndrome; and Relday, an injectable formulation of risperidone that is in Phase Ib clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) decreased -6.00%, and closed at $115.62. The stock has price to sale ratio of 24.50, however, price to book ratio is 11.21. With recent decline, the year-to-date (YTD) performance reflected a 27.99% incline below last year. During the past month the stock gain 7.55%, bringing three-month performance to 31.12% and six-month performance to 62.14%. The mean recommendation of analysts for this stock is 1.80 (where 1=Buy, 5=Sale).
BioMarin Pharmaceutical Inc. (BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease.
Skyworks Solutions Inc (NASDAQ:SWKS) decreased -5.81%, and closed at $95.57. The company holds the market capitalization of $19.36 B. For the last twelve months, the stock was able to keep return on equity at 22.50%, while return on assets at 19.60%, in response to its return on investment at 18.10%. Its 20-day moving average gained 2.01%, above 50-day moving average of 11.55%, above 200-day moving average of 49.03% from the latest market price of $95.57. The mean recommendation of analysts for this stock is 1.80. (Where 1=Buy, 5=Sale).
Skyworks Solutions Inc (SWKS) together with its subsidiaries, designs, develops, manufactures, and markets analog and mixed signal semiconductors worldwide. Its product portfolio includes amplifiers, attenuators, battery chargers, circulators, DC/DC converters, demodulators, detectors, diodes, directional couplers, filters, front-end modules, hybrids, infrastructure radio frequency subsystems, isolators, LED drivers, mixers, modulators, optocouplers, optoisolators, phase shifters, phase locked loops/synthesizers/VCOs, power dividers/combiners, power management devices, receivers, switches, technical ceramics, and voltage regulators.
Opko Health Inc. (NYSE:OPK) fell -5.96%, and closed at $13.88. The stock has the beta value of 0.96, and its volatility for the week is 3.91%, while for the month it is 3.39%. The company has the market capitalization of $6.67 billion. The company holds the book value per share of 1.95, whereas cash per share is 0.21. Price to book ratio remained 7.12, while price to sale ratio is 68.81. Analysts mean recommendation for the stock is said to be 1.70 (where 1=Buy, 5=sale).
Opko Health Inc. (OPK) a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics. The company develops various solutions to diagnose, treat, and prevent various conditions, including point-of-care tests, molecular diagnostics tests, laboratory developed tests, and proprietary pharmaceuticals and vaccines.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
